Search results for "direct cost"

showing 10 items of 59 documents

Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe

2005

International audience; Background: Resource utilisation and direct costs associated with glaucoma progression in Europe are unknown. As population progressively ages, the economic impact of the disease will increase. Methods: From a total of 1655 consecutive cases, the records of 194 patients were selected and stratified by disease severity. Record selection was based on diagnoses of primary open angle glaucoma, glaucoma suspect, ocular hypertension, or normal tension glaucoma; 5 years minimum follow up were required. Glaucoma severity was assessed using a six stage glaucoma staging system based on static threshold visual field parameters. Resource utilisation data were abstracted from the…

Maleage distributionOrganes des sensgenetic structuresOffice VisitsOcular hypertensionGlaucomaDiseaseintraocular hypertensionSeverity of Illness IndexIndirect costs0302 clinical medicineambulatory careNormal tension glaucomamiddle agedopen angle glaucoma80 and overMedicine030212 general & internal medicinepathophysiologystatistical significanceAged 80 and overeducation.field_of_studyadultdisease coursearticlehealth care costclinical trialHealth Care Costshealth care planningSensory Systems3. Good healthEuropeagedfemalepriority journalstatisticsHealth Resourcesdisease severityadult; aged; article; disease course; disease severity; Europe; female; follow up; general practitioner; glaucoma; health care cost; health care utilization; human; intraocular hypertension; major clinical study; male; medical record; open angle glaucoma; priority journal; statistical significance; visual field; age distribution; ambulatory care; clinical trial; drug cost; economics; health care planning; hospitalization; middle aged; multicenter study; pathophysiology; sex ratio; statistics; utilization review; Adult; Age Distribution; Aged; Aged 80 and over; Drug Costs; Europe; Female; Follow-Up Studies; Glaucoma; Health Care Costs; Health Resources; Humans; Male; Middle Aged; Office Visits; Severity of Illness Index; Sex Distribution; Visual Fieldshospitalizationvisual fieldWorld Viewsmedicine.medical_specialtyOpen angle glaucomadrug costPopulationSensory OrgansMédecine humaine et pathologiemedical recordDrug Costs03 medical and health sciencesCellular and Molecular Neurosciencehealth care utilizationSeverity of illnessfollow upHumanshumanSex Distribution[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organseducationutilization reviewSettore MED/30 - Malattie Apparato Visivobusiness.industryGlaucomaeconomicssex ratiomedicine.diseasemajor clinical studyeye diseasesOphthalmologymulticenter studygeneral practitionerEmergency medicine030221 ophthalmology & optometryOptometryHuman health and pathologyVisual Fieldsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Cost of Type 2 Diabetes Patients with Chronic Kidney Disease Based on Real-World Data: An Observational Population-Based Study in Spain

2021

[EN] This study analyzed the prevalence, costs and economic impact of chronic kidney disease CKD in patients with T2D in a Spanish Health District using real-world data. Observational cross-sectional study in adult patients with T2D was through data extracted from the information systems of the Valencia Clinico-La Malvarrosa Health District in the year 2015. Patients were stratified with the KDIGO classification for CKD. Additionally, patients were assigned to Clinical Risk Groups (CRGs) according to multimorbidity. Direct costs of primary and specialized care, and medication were estimated. The prevalence of T2D in the database population (n = 28,345) was 10.8% (mean age (SD) = 67.8 years …

Malehealthcare resourcesmedicine.medical_specialtyECONOMIA APLICADAHealth Toxicology and MutagenesisPopulationRenal functioncostsType 2 diabetesDiseaseArticleIndirect costsChronic kidney diseaseInternal medicineHealth caremedicineHumansRenal Insufficiency ChronicHealthcare resourcesBurden of careeducationAgededucation.field_of_studyDiabetisbusiness.industryClinical Risk GroupsPublic Health Environmental and Occupational HealthRType 2 diabetesHealth Care Costsmedicine.diseaseCostsKDIGO classificationCross-Sectional StudiesDiabetes Mellitus Type 2Spainburden of careInsuficiència renal crònicaMedicineFemaleObservational studyECONOMIA FINANCIERA Y CONTABILIDADtype 2 diabetesbusinesschronic kidney diseaseKidney diseaseInternational Journal of Environmental Research and Public Health
researchProduct

Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients.

2012

Abstract Purpose The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). Patients and methods This study included all patients treated with DEB-TACE in our hospital between January 2009 and December 2010. All patients received DEB-TACE on demand and were evaluated after each session. Results Twenty-one patients received an average of 1.3 sessions. The median time to treatment discontinuation and median progression-free survival was 181 days and 295 days, respectively. Toxicity caused treatment discontinuation in thr…

Malemedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaCostResultDrug Delivery SystemsTransarterial chemoembolisationOn demandmedicineHumansRadiology Nuclear Medicine and imagingIn patientChemoembolization TherapeuticAgedRetrospective StudiesAged 80 and overRadiological and Ultrasound TechnologyDrug eluting beadsbusiness.industryLiver NeoplasmsGeneral MedicineDirect costMiddle Agedmedicine.diseaseDrug eluting beadsMicrospheresSurgeryDiscontinuationTreatment OutcomeMedian timeHepatocellular carcinomaCosts and Cost AnalysisFemaleProspective payment systembusinessDiagnostic and interventional imaging
researchProduct

Osteoporosis: Economic Burden of Disease in Italy.

2020

Background and Objective: Today, osteoporosis is the most common bone disease and an important public health problem in all developed countries. The objective of this study was to estimate the costs associated with the management and treatment of osteoporosis in order to assess the economic burden in Italy for 2017, in terms of direct medical costs and social security costs. Methods: A cost of illness model was developed to estimate the average cost per year sustained by the NHS (National Health Service) and Social Security System in Italy. A systematic literature review was performed to obtain epidemiological, direct and indirect costs parameters where available. Hospitalisation costs were…

Patient Discharge.Malemedicine.medical_specialtySettore SECS-P/06accountingalliedhealth030204 cardiovascular system & hematology030226 pharmacology & pharmacyState MedicineServizio Sanitario Nazionale03 medical and health sciencesIndirect costs0302 clinical medicineCost of IllnessInternational Classification of DiseasesEnvironmental healthEpidemiologyInternational Classification of DiseasemedicineHumansPharmacology (medical)health care economics and organizationsAverage costAgedPensionbusiness.industryPublic healthOsteoporosieconomicsAged; Female; Health Care Costs; Hospitalization; Humans; International Classification of Diseases; Italy; Male; Middle Aged; Osteoporosis; Patient Discharge; State Medicine; Cost of IllnessGeneral MedicineHealth Care Costsosteoporosi Italia Servizio Sanitario NazionaleMiddle AgedItaliaPatient DischargeHealth Care CostSocial securityHospitalizationSystematic reviewItalySettore MED/42OsteoporosisFemalebusinessDeveloped countryHumanClinical drug investigation
researchProduct

The global burden of chronic urticaria for the patient and society*

2020

Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25-75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1 -antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1 -antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients' quality of life and the burden of this …

Pediatricsmedicine.medical_specialtyUrticariaOmalizumabDermatologyOmalizumabDisease030207 dermatology & venereal diseases03 medical and health sciencesIndirect costs0302 clinical medicineQuality of lifemedicineHumansChronic UrticariaDepression (differential diagnoses)business.industryUrticària -- TractamentDermatology Life Quality IndexMiddle AgedSalut públicaEuropeSexual dysfunctionQualitat de vidaChronic DiseasePresenteeismQuality of LifeIndicadors econòmicsFemalemedicine.symptombusinessmedicine.drugBritish Journal of Dermatology
researchProduct

Gestión de la devolución de tratamientos antineoplásicos y de su reutilización en pacientes oncológicos

2009

Objective: Analyse the profi le of parenteral preparation and treatment (anti-neoplastic and supplementary) that were dispensed and returned to the Pharmacy Department, the reasons why they were not administered, their reuse and the associated direct costs. Method: Longitudinal study over eight months (October 2004-May 2005) in a tertiary hospital with centre for preparing anti-neoplastic agents (including supplementary treatment) in its Pharmacy Department. The variables studied, downloaded from the Oncofarm® application, are as follows: a) patients and diagnostics; b) returned treatments, classifi ed by reason returned, pharmaco-therapeutic scheme, cycle and day; c) returned preparations …

Pharmacologymedicine.medical_specialtyIndirect costsbusiness.industryInternal medicinemedicineSafety criteriaPharmacybusinessLevofolinic acidSurgeryFarmacia Hospitalaria
researchProduct

The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design.

2021

Up to 80% of first-episode psychosis patients suffer a relapse within five years of the remission. Relapse should be an important focus of prevention given the potential harm to the patient and family. It threatens to disrupt their psychosocial recovery, increases the risk of resistance to treatment and has been associated with greater direct and indirect costs for society. Based on a previous project entitled "Genotype-phenotype and environment. Application to a predictive model in first psychotic episodes" (PEPs Project), the project "Clinical and neurobiological determinants of second episodes of schizophrenia. Longitudinal study of first episode of psychosis" was designed, also known as…

PsychosisLongitudinal studymedicine.medical_specialtyIndirect costs03 medical and health sciences0302 clinical medicineRecurrenceIntervention (counseling)medicineHumansLongitudinal StudiesPsychiatryFirst episodebusiness.industryNeuropsychologyGeneral Medicinemedicine.disease030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniabusinessPsychosocial030217 neurology & neurosurgeryFollow-Up StudiesRevista de psiquiatria y salud mental
researchProduct

Economic costs associated with acute attacks and long-term management of hereditary angioedema.

2010

Background Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent acute attacks of swelling of the larynx, abdomen, and periphery. Objective To assess the economic burden associated with acute attacks and long-term management of HAE. Methods Burden was assessed via a Web-based survey of HAE patients (≥18 years old) that solicited information on attack characterization, short-term treatment, long-term disease management, impact on work, and patient costs. A standardized instrument, the Work Productivity and Activity Impairment questionnaire, was included to assess impact on work productivity. Standard medical costs and US average wage costs were assigned…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyEmergency Medical Servicesmedia_common.quotation_subjectImmunologyWageDrug CostsIndirect costsCost of IllnessEconomic costSurveys and QuestionnairesLong term managementmedicineImmunology and AllergyHumansDisease management (health)Hospital CostsProductivityhealth care economics and organizationsmedia_commonbusiness.industryAngioedemas HereditaryEmergency departmentHealth Care Costsmedicine.diseaseHospitalizationHealth Care SurveysEmergency medicineHereditary angioedemaAcute DiseasePhysical therapyFemalebusinessAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

The whole story: treatment outcomes with SymbicortS

2002

Asthma is a chronic inflammatory disorder of the airways that has a considerable socioeconomic impact. Asthma management guidelines have been introduced to help provide better long-term control of asthma. Although recommended guidelines may increase the direct medication costs, the overall direct costs of asthma may be reduced due to fewer exacerbations. In addition, indirect costs due to lost productivity and mortality are reduced and patients have an improved quality of life. Inhaled corticosteroids are first-line therapy in the treatment of persistent asthma. Against this background, we have assessed the cost-effectiveness of Symbicort (budesonide and formoterol in a single inhaler), a t…

Pulmonary and Respiratory MedicineBudesonidemedicine.medical_specialtybusiness.industrymedicine.drug_classCost effectivenessInhalermedicine.diseaserespiratory tract diseasesIndirect costsQuality of lifeimmune system diseasesBronchodilatormedicineFormoterolIntensive care medicinebusinessAsthmamedicine.drugRespiratory Medicine
researchProduct

A Bayesian cost-effectiveness analysis of a telemedicine-based strategy for the management of sleep apnoea: a multicentre randomised controlled trial

2015

Background Compliance with continuous positive airway pressure (CPAP) therapy is essential in patients with obstructive sleep apnoea (OSA), but adequate control is not always possible. This is clinically important because CPAP can reverse the morbidity and mortality associated with OSA. Telemedicine, with support provided via a web platform and video conferences, could represent a cost-effective alternative to standard care management. Aim To assess the telemedicine impact on treatment compliance, cost-effectiveness and improvement in quality of life (QoL) when compared with traditional face-to-face follow-up. Methods A randomised controlled trial was performed to compare a telemedicine-bas…

Pulmonary and Respiratory MedicineMaleTelemedicinemedicine.medical_specialtyEpidemiologymedicine.medical_treatmentCost-Benefit Analysislaw.inventionIndirect costsClinical trialsQuality of lifeRandomized controlled triallawmedicineHumansContinuous positive airway pressureProspective StudiesDisease management (health)EpidemiologiaTelecommunication in medicineSleep apnea syndromesPrimary health careSleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industryDisease ManagementBayes TheoremCost-effectiveness analysisSíndromes d'apnea del sonMiddle AgedTelemedicinenervous system diseasesrespiratory tract diseasesClinical trialAtenció primàriaPhysical therapyQuality of LifePatient ComplianceFemalebusinessSleepFollow-Up StudiesTelecomunicació en medicinaAssaigs clínics
researchProduct